Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | WNT1 | P04628 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2976731 | 0.99 | F10 (0.98) | F10F2WNT1GSK3BDYRK1A | |
| SCHEMBL13206717 | 0.93 | F10 (0.86) | F10F2WNT1GSK3BDYRK1A | |
| SCHEMBL2473807 | 0.92 | F10 (1.00) | F10F2WNT1GSK3BDYRK1A | |
| SCHEMBL2987629 | 0.92 | F10 (0.85) | F10F2WNT1GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL2983033 | 0.91 | F10 (0.84) | F10F2WNT1GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL2983388 | 0.91 | F10 (0.98) | F10F2WNT1GSK3BDYRK1A | |
| SCHEMBL13206713 | 0.89 | F10 (0.80) | F10F2NR3C1MAPK1RAB9A | |
| Malonic Acid SCHEMBL6276933 | 0.88 | F10 (0.92) | F10F2WNT1GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL2993202 | 0.88 | F10 (0.79) | F10F2NR3C1MAPK1RAB9A | |
| SCHEMBL13206805 | 0.86 | F10 (0.75) | F10F2MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504417-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2009-03-17 | — | — | US | claimed |
| EP-1336605-B1 | SUBSTITUTED PHENOL DERIVATIVES OR SALTS THEREOF AS INHIBITORS OF COAGULATION FACTOR X | ASTELLAS PHARMA INC (JP) | 2006-04-12 | — | — | EP | claimed |
| US-20040077555-A1 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2004-04-22 | — | — | US | claimed |
| EP-1336605-A1 | SUBSTITUTED BENZENE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-08-20 | — | — | EP | claimed |
| US-7786106-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786106-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786106-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20090137498-A1 | such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism | ASTELLAS PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137498-A1 | such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism | ASTELLAS PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137498-A1 | such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism | ASTELLAS PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7504417-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-7504417-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-7504417-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2009-03-17 | — | — | US | disclosed |
| EP-1336605-B1 | SUBSTITUTED PHENOL DERIVATIVES OR SALTS THEREOF AS INHIBITORS OF COAGULATION FACTOR X | ASTELLAS PHARMA INC (JP) | 2006-04-12 | — | — | EP | disclosed |
| US-20040077555-A1 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1336605-A1 | SUBSTITUTED BENZENE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077555-A1 | Substituted benzene derivatives or salts thereof | F12, F2, HABP2 | F10 5/4885F2 2/4885WNT1 4158/4885 |
| US-20090137498-A1 | such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism | PLG, MGAT3, F11 | F10 4/4885F2 8/4885WNT1 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.